On the contrary, in treatment-naive glioblastoma, reduced ADC values before antiangiogenic therapy correlated with better outcomes, possibly due to an association with MGMT methylation, highlighting the genetic differences of untreated and recurrent glioblastomas (81). The gene discussed is MGMT; the disease is glioblastoma.